Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ablynx, Bioverativ Buys Drive Sanofi's Hematology Reign

Executive Summary

Sanofi's €3.9bn acquisition of Ablynx will allow the French big pharma to build up its rare blood disorder pipeline and bring in complementary programs in areas like respiratory infections.

Advertisement

Related Content

Roche $4.8bn Buy Sparks Hemophilia Gene Therapy Race
Biopharma Quarterly Dealmaking Statistics, Q1 2018
Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
Novo To Secure Licensing Or M&A Deal By Mid-2018
Sanofi Builds Blood Disorder Specialty With Bioverativ Buy
Novo's €2.6bn Ablynx Bid Opens The Door For Better Offers
Ablynx Adds Sanofi To Its List Of Big Pharma Partners
Sanofi Pasteur, AstraZeneca Link To Develop MEDI8897 Infant RSV Vaccine

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100282

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel